We are monitoring the impact of COVID-19 on APAC Cancer Monoclonal Antibodies Market Get in touch with us for detailed analysis Know More
Pulished Date April, 2021
ID: 160
Share on
Share on

Asia Pacific Cancer Monoclonal Antibodies Market Research Report – Segmented By Application, Type, Conjugated Cancer Therapies & Country (India, China, Japan, South Korea, Australia, New Zealand, Thailand, Malaysia, Vietnam, Philippines, Indonesia, Singapore and Rest of APAC) - Industry Analysis on Size, Share, Trends & Growth Forecast (2021 to 2026)

Pulished: April, 2021
ID: 160
Pages: 145

APAC Cancer Monoclonal Antibodies Market Size (2020 to 2025)

The size of the Cancer Monoclonal Antibodies Market in the Asia Pacific was valued at USD 5.94 billion in 2018 and is forecasted to be a USD 10.95 Billion market by 2023 with a tremendous growth rate 13%.

Increasing incidences of cancer diseases is a key driving factor for growth in the Asia Pacific. Rising awareness over the availability of several treatment procedures for cancer disease is another attribute elevating the demand of the cancer monoclonal antibodies market in this region. Favorable conditions from the government to manufacture quality medicines for cancer patients at affordable prices are expanding the market shares. Adopting a sedentary lifestyle and changes in food habits also fuelled the demand for the cancer monoclonal antibodies market in the Asia Pacific.

However, the government's stringent rules and regulations in approving new drugs are slowly inhibiting the demand of the market. People in rural areas are unaware of cancer treatment procedures, which is a big challenging factor for market players. Lack of standardization is also to impact negatively on the growth of the market in the Asia Pacific. The dearth of skilled people in manufacturing quality drugs with the latest technology in undeveloped countries limits the growth rate of the cancer monoclonal antibodies market.

Growth opportunities for the market lie in the growing support from both private and public organizations through funds. The launch of innovative techniques with the latest technologies to treat cancer is expanding the market shares in the Asia Pacific.

This research report on the Asia Pacific Cancer Monoclonal Antibodies Market has been segmented and sub-segmented into the following categories:

By Application: 

  • Liver
  • Breast
  • Blood
  • Brain
  • Hodgkin’s And Non-Hodgkin’s Lymphoma
  • Colorectal
  • Leukemia
  • Others

By Type: 

  • Murine Antibodies
  • Chimeric & Humanised Antibodies
  • Fully Humanized Antibodies

By Conjugated Cancer Therapies: 

  • Immunoliposome
  • Radioimmunotherapy
  • ADEPT
  • Immunocytokines
  • Others

By Country: 

  • India
  • China
  • Japan
  • South Korea
  • Australia
  • New Zealand
  • Thailand
  • Malaysia
  • Vietnam
  • Philippines
  • Indonesia
  • Singapore
  • Rest of APAC

Regionally, India, and China are the major countries contributing to the highest shares for the market. Constant economic growth and the increasing geriatric population are two factors propelling the demand of the market. Japan and Australia are holding significant shares next to India and China by manufacturing quality drugs and taking steps to improve the treatment procedures in hospitals with the latest technology. The rest of the Asia Pacific is to have significant growth opportunities in foreseen years with the government's rising support.

Prominent companies dominating the APAC Cancer Monoclonal Antibodies Market profiled in this report are Amgen, Genmab, Briston Myers Squibb, GlaxoSmithKline, Eli Lilly, Roche, Immunogen, Seattle Genetics, Novartis & Spectrum Pharmaceuticals.

  1. Introduction

                1.1 Market Definition    

                1.2 Study Deliverables  

                1.3 Base Currency, Base Year and Forecast Periods          

                1.4 General Study Assumptions

  1. Research Methodology

                2.1 Introduction               

                2.2 Research Phases      

                                2.2.1 Secondary Research

                                2.2.2 Primary Research

                                2.2.3 Econometric Modelling

                                2.2.4 Expert Validation

                2.3 Analysis Design         

                2.4 Study Timeline          

  1. Overview

                3.1 Executive Summary

                3.2 Key Inferences         

                3.3 New Developments               

  1. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)

                4.1 Market Drivers          

                4.2 Market Restraints    

                4.3 Key Challenges         

                4.4 Current Opportunities in the Market              

  1. Market Segmentation

                5.1 By Application           

                                5.1.1 Liver

                                5.1.2 Breast

                                5.1.3 Brain

                                5.1.4 Blood

                                5.1.5 Hodgkins and Non-Hodgkins lymphoma

                                5.1.6 Colorectal

                                5.1.7 Leukaemia

                                5.1.8 Others

                5.2 By Type        

                                5.2.1 Murine Antibodies

                                5.2.2 Chimeric and Humanised Antibodies

                                5.2.3 Fully Humanized Antibodies

                5.3 Conjugate Cancer Therapies               

                                5.3.1 Immunoliposome

                                5.3.2 Radioimmunotherapy

                                5.3.3 ADEPT

                                5.3.4 Immunocytokines

                                5.3.5 Others

  1. Geographical Analysis

                6.1 Introduction               

                6.2 China             

                6.3 India              

                6.4 Japan            

                6.5 South Korea               

  1. Strategic Analysis

                7.1 PESTLE analysis         

                                7.1.1 Political

                                7.1.2 Economic

                                7.1.3 Social

                                7.1.4 Technological

                                7.1.5 Legal

                                7.1.6 Environmental

                7.2 Porter’s Five analysis              

                                7.2.1 Bargaining Power of Suppliers

                                7.2.2 Bargaining Power of Consumers

                                7.2.3 Threat of New Entrants

                                7.2.4 Threat of Substitute Products and Services

                                7.2.5 Competitive Rivalry within the Industry

  1. Market Leaders' Analysis

                8.1 Roche

                                8.1.1 Overview

                                8.1.2 Product Analysis

                                8.1.3 Strategic Evaluation and Operations

                                8.1.4 Financial analysis

                                8.1.5 Legal issues

                                8.1.6 Recent Developments

                                8.1.7 SWOT analysis

                                8.1.8 Analyst View

                8.2 Amgen

                8.3 Genmab

                8.4 Glaxosmithkline

                8.5 Bristol Meyer Squibb

                8.6 Eli Lilly

                8.7 Immunogen

                8.8 Novartis

                8.9 Seattle Genetics

                8.10 Spectrum Pharmaceuticals

  1. Competitive Landscape

                9.1 Market share analysis            

                9.2 Merger and Acquisition Analysis       

                9.3 Agreements, collaborations and Joint Ventures         

                9.4 New Product Launches         

  1. Expert Opinions

                10.1 Market Outlook     

                10.2 Investment Opportunities 

     Appendix                           

  1. List of Tables
  2. List of Figures
  • Regional, and country-level analysis and forecasts of the study market; providing Insights on the major countries/regions in which this industry is blooming and to also identify the regions that are still untapped
  • Segment-level analysis in terms of technology, component, and type along with market size forecasts and estimations to detect key areas of industry growth in detail
  • Identification of key drivers, restraints, opportunities, and challenges (DROC) in the market and their impact on shifting market dynamics
  • Study of the effect of exogenous and endogenous factors that affect the global market; which includes broadly demographic, economics, and political, among other macro-environmental factors presented in an extensive PESTLE Analysis
  • Study the micro environment factors that determine the overall profitability of an Industry, using Porter’s five forces analysis for analysing the level of competition and business strategy development
  • A comprehensive list of key market players along with their product portfolio, current strategic interests, key financial information, legal issues, SWOT analysis and analyst overview to study and sustain the market environment
  • Competitive landscape analysis listing out the mergers, acquisitions, collaborations in the field along with new product launches, comparative financial studies and recent developments in the market by the major companies
  • An executive summary, abridging the entire report in such a way that decision-making personnel can rapidly become acquainted with background information, concise analysis and main conclusions
  • Expertly devised analyst overview along with Investment opportunities to provide both individuals and organizations a strong financial foothold in the market
  1. Asia-Pacific Cancer Monoclonal Antibodies Market, By Region, From 2020 to 2025 (USD Million)
  2. Asia-Pacific Cancer Monoclonal Antibodies Market, By Application, From 2020 to 2025 (USD Million)
  3. Asia-Pacific Liver Market, By Region, From 2020 to 2025 (USD Million)
  4. Asia-Pacific Breast Market, By Region, From 2020 to 2025 (USD Million)
  5. Asia-Pacific Brain Market, By Region, From 2020 to 2025 (USD Million)
  6. Asia-Pacific Blood Market, By Region, From 2020 to 2025 (USD Million)
  7. Asia-Pacific Hodgkins and Non-Hodgkins lymphoma Market, By Region, From 2020 to 2025 (USD Million)
  8. Asia-Pacific Colorectal Market, By Region, From 2020 to 2025 (USD Million)
  9. Asia-Pacific Leukaemia Market, By Region, From 2020 to 2025 (USD Million)
  10. Asia-Pacific Others Market, By Region, From 2020 to 2025 (USD Million)
  11. Asia-Pacific Cancer Monoclonal Antibodies Market, By Type, From 2020 to 2025 (USD Million)
  12. Asia-Pacific Murine Antibodies Market, By Region, From 2020 to 2025 (USD Million)
  13. Asia-Pacific Chimeric and Humanised Antibodies Market, By Region, From 2020 to 2025 (USD Million)
  14. Asia-Pacific Fully Humanized Antibodies Market, By Region, From 2020 to 2025 (USD Million)
  15. Asia-Pacific Cancer Monoclonal Antibodies Market, By Conjugate Cancer Therapies, From 2020 to 2025 (USD Million)
  16. Asia-Pacific Immunoliposome Market, By Region, From 2020 to 2025 (USD Million)
  17. Asia-Pacific Radioimmunotherapy Market, By Region, From 2020 to 2025 (USD Million)
  18. Asia-Pacific ADEPT Market, By Region, From 2020 to 2025 (USD Million)
  19. Asia-Pacific Immunocytokines Market, By Region, From 2020 to 2025 (USD Million)
  20. Asia-Pacific Others Market, By Region, From 2020 to 2025 (USD Million)
  21. Cancer Monoclonal Antibodies Market, By Application, From 2020 to 2025 (USD Million)
  22. Liver Market, By Region, From 2020 to 2025 (USD Million)
  23. Breast Market, By Region, From 2020 to 2025 (USD Million)
  24. Brain Market, By Region, From 2020 to 2025 (USD Million)
  25. Blood Market, By Region, From 2020 to 2025 (USD Million)
  26. Hodgkins and Non-Hodgkins lymphoma Market, By Region, From 2020 to 2025 (USD Million)
  27. Colorectal Market, By Region, From 2020 to 2025 (USD Million)
  28. Leukaemia Market, By Region, From 2020 to 2025 (USD Million)
  29. Others Market, By Region, From 2020 to 2025 (USD Million)
  30. China Cancer Monoclonal Antibodies Market, By Application, From 2020 to 2025 (USD Million)
  31. China Cancer Monoclonal Antibodies Market, By Type, From 2020 to 2025 (USD Million)
  32. China Cancer Monoclonal Antibodies Market, By Conjugate Cancer Therapies, From 2020 to 2025 (USD Million)
  33. India Cancer Monoclonal Antibodies Market, By Application, From 2020 to 2025 (USD Million)
  34. India Cancer Monoclonal Antibodies Market, By Type, From 2020 to 2025 (USD Million)
  35. India Cancer Monoclonal Antibodies Market, By Conjugate Cancer Therapies, From 2020 to 2025 (USD Million)
  36. Japan Cancer Monoclonal Antibodies Market, By Application, From 2020 to 2025 (USD Million)
  37. Japan Cancer Monoclonal Antibodies Market, By Type, From 2020 to 2025 (USD Million)
  38. Japan Cancer Monoclonal Antibodies Market, By Conjugate Cancer Therapies, From 2020 to 2025 (USD Million)
  39. South Korea Cancer Monoclonal Antibodies Market, By Application, From 2020 to 2025 (USD Million)
  40. South Korea Cancer Monoclonal Antibodies Market, By Type, From 2020 to 2025 (USD Million)
  41. South Korea Cancer Monoclonal Antibodies Market, By Conjugate Cancer Therapies, From 2020 to 2025 (USD Million)

Please wait. . . . Your request is being processed

Related Reports

LICENCE TYPE

$ 1234 3335

Clients
clients
clients
clients
clients
clients
clients
Click for Request Sample